<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083719</url>
  </required_header>
  <id_info>
    <org_study_id>AHD1234</org_study_id>
    <nct_id>NCT01083719</nct_id>
  </id_info>
  <brief_title>A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.</brief_title>
  <official_title>Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medanta Institute of Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medanta Institute of Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESIS AND SAMPLE SIZE The tumor delineated by FDG-PET is significantly different from
      the delineation achieved by MR T1 contrast weighted images in glioblastoma; expecting a
      standard error of 12.5 % (a confidence interval of 25%), with a confidence level set at 95%,
      a sample size of 15 patients would be accrued in the study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor infiltration defined on FDG-PET not determined to MRI</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>FDG-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FDG-PET</intervention_name>
    <description>Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma</description>
    <arm_group_label>FDG-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Post operative patients of documented high grade gliomas (grade III and IV)

          2. Patients who have not undergone any previous irradiation to brain.

          3. Performance Scale as defined by ECOG PS 0-3

        Exclusion Criteria:

          1. Patients who are diabetic.

          2. Patients who are pregnant.

          3. Any documented contrast allergy to the agents used for imaging.

          4. Patients who are unable to comprehend or cooperate effectively for treatment planning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tejinder kataria/ principal Investigator</name_title>
    <organization>Medanta- The medicity</organization>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

